Login to Your Account



Trimeris, Roche Place Hold On T-1249; Trimeris Reduces Staff

By Kim Coghill


Wednesday, January 7, 2004
A decision reached by Trimeris Inc. and F. Hoffmann-La Roche Ltd. to halt clinical development of the early-stage HIV candidate T-1249 did not trigger a stock slide of devastating proportions for Trimeris, the company that discovered Fuzeon, a first-in-class fusion inhibitor for HIV patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription